Abstract
Acromegaly is due to excess Growth hormone (GH) production, usually a result of pituitary adenoma. The diagnosis is often preceded by around 5 years of the active but unrecognized disease. Clinical expression of the disease in each patient depends on the levels of GH and Insulin-like Growth Factor-1 (IGF-1), age, tumor size, and the delay in diagnosis. Successful remission after Trans-sphenoidal surgery (TSS) is reported to be found in 52.5% of cases in the developed countries. It was a Descriptive cohort study. Total 84 patients with biochemical and radiological diagnoses of Acromegaly were included in the study between January, 2005 to December, 2019. Patients’ medical record files were reviewed & data recorded Of the 84 subjects, with a mean age of 38.69 ± 13.52 years, 54 (64.3%) were male while 30 (35.7%) were female. The patients presented at a mean duration of 5.43 ± 4.3 years after the onset of symptoms. The most frequent complaint was somatic growth features in the form of enlarged hands & feet noted by 81 (96.4%) pts. Overall, 73 (86.9%) patients underwent TSS for removal of pituitary adenoma while 11 (13.1%) patients refused to opt for the surgical option. Only 9 (12.3%) patients achieved biochemical & radiological remission after 6 months of surgery. Among 64 patients with persistent disease after TSS, 38 (59.4%) were treated with radiosurgery/radiotherapy, 15 (23.4%) underwent repeat TSS and 11 (17.2%) opted for medical treatment, mostly with Cabergoline. TSS is followed by the documentation of a high rate (88%) of failure to achieve remission and the majority of patients have to opt for radiotherapy/repeat TSS for the persistent disease. With the continuously improving surgical skills, we expect that the figures attaining remission after primary TSS will rise in the decades to come.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have